INTRODUCTION
The mammalian innate immune system identifies the presence of infection through recognition of pathogen-associated molecular patterns (PAMPs) expressed by a diverse group of infectious microorganisms. Various pattern recognition receptors are involved in PAMP identification, among which the toll-like receptor (TLR) family of at least 10 different members in humans (1;2) is probably the best known. These receptors are considered sensors for microbial infections or other "danger signals" and, together with other molecular sensors, serve as a first line of defense, inducing soluble and cellular mediators of innate immunity and initiating key steps of the adaptive immune response (3) . Particular clinical interest now revolves around TLR9, which is expressed not only on cells of the immune system but also on endothelial cells, fibroblasts, and epithelial cells (3) (4) (5) (6) and which recognizes bacterial and viral DNA with unmethylated CpG motifs.
Synthetic oligodeoxynucleotides (ODN) expressing CpG motifs mimic the immunestimulatory activity of bacterial DNA and are commonly used to activate TLR9 for therapeutic applications (3) . CpG-ODN have demonstrated anti-tumor activity in different animal models (7;8) and in patients with malignant melanoma, renal carcinoma and recurrent or refractory lymphoma (9) (10) (11) (12) ; however, experimental studies suggest that CpG-ODN may be more useful as a component of multi-agent therapy for cancer rather than as a single agent (13) . Since chemotherapy is known to be immunosuppressive, it may seem counterintuitive to combine it with TLR9 stimulation. Nevertheless, different chemotherapeutic drugs have been reported to improve the efficacy of CpG-ODN in mouse tumor models (14;15) . In immunocompetent mice, paclitaxel and 5 cyclophosphamide enhanced CpG-ODN effects by depleting regulatory T cells, increasing the immunogenicity of tumor cells, and changing T cell homeostasis; moreover, the presence of CD8 + T cells was found to be required (16). In immunocompromised athymic mice, the mechanisms underlying the improved antitumor effect when CpG-ODN was combined with gimatecan (17) , gemcitabine (6) (24) , and assessed the anti-tumor effect of CpG-ODN associated with DNAdamaging chemotherapy in this mouse model.
MATERIALS AND METHODS

Cell lines
The IGROV-1 tumor (gift from Dr. J. Benard, Institute Gustave Roussy, Villejuif, France) and OVCAR-5 (American Type Culture Collection) were adapted to grow i.p.
and maintained by serial i.p. passage of ascitic cells into healthy mice as previously described (25) . Every six months, cells were authenticated by morphologic inspection and by the presence of specific markers with FACS analysis. For in vitro experiments, cells were maintained in RPMI medium 1640 supplemented with 10% FCS (Sigma) and 2 mM glutamine (Cambrex, East Rutherford, NJ) at 37°C in a 5% CO 2 air atmosphere.
In vitro and in vivo experiments for microarray analyses
For microarray experiments, mice were injected i.p. with 2.5 x 10 6 ascitic cells in 0. (27) (28) (29) (30) (31) (32) . Table 1A ).
As shown in Figure. 5A, patients of the "CpG-like" group showed a significantly increased overall survival compared to the "CpG-untreated-like" group. To test the relevance of RAD23B in the sensitivity to DNA-damaging agents in IGROV-1 cell line, we down-regulated RAD23B protein levels by specific siRNA transfection (Supplementary Figure 6A) . In vitro cisplatin cytotoxicity is significantly reduced (p<0.0001) by down-regulation of RAD23B (Supplementary Figure 6B) .
When Kaplan-Meier survival analysis was performed on a breast cancer dataset of wholegenome expression of patients who received adjuvant DNA-damaging chemotherapy after surgery (37), patients classified as "CpG-like" showed a significantly increased relapse-free and overall survival compared to "CpG-untreated-like" patients ( Figure 5B) ; on the contrary, no outcome difference was observed in the cohort of patients not treated with DNA damaging adjuvant therapy ( Figure. 5C ).
In chemotherapy treated patients, "CpG-like" signature was significantly associated with grade (1+2) (p=0.0048), whereas no association was found with the other pathologic parameters (estrogen receptor, tumor size and node status) (Supplementary Table 2A ).
Multivariate analysis of all covariates (i.e. estrogen receptor, tumor size, grade, node status and "CpG-like" signature) indicated that CpG-like signature resulted an independent strong prognostic factor (HR=0.3875, 95%CI=0.1812-0.8287, p=0,015) of relapse-free survival (Supplementary Table 2B ).
Altogether, these findings indicate that CpG-ODN modulate DNA repair gene expression that are relevant for cell sensitivity to DNA-damages
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